November 19, 2026 · The American journal of emergency medicine · DOI: 10.1016/j.ajem.2026.11.017

Activated partial thromboplastin time following Kcentra® versus Balfaxar® reversal of apixaban, rivaroxaban, and warfarin: a propensity-score matched cohort study.

Listen to this summary

This single-center, propensity-score matched cohort study asked whether aPTT changes differ between two four-factor prothrombin complex concentrates, Kcentra® and Balfaxar®, used to reverse apixaban, rivaroxaban, or warfarin, despite Balfaxar® containing substantially more heparin. In 30 matched patients (15 per group), aPTT changes were small and not significantly different (median difference 2 s, p = 0.468), and no significant differences were found in hemostatic effectiveness, thrombotic events, or mortality. However, the very small sample and wide confidence intervals mean the study cannot establish clinical equivalence, and larger studies focused on patient-centered outcomes are needed.

Nataly A Guirguis, Elizabeth A Feldman, Patrick G Rose, Christopher D Miller, Robert W Seabury

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play